Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

Annals of the Rheumatic Diseases

Volumn 73, Issue 7, 2014, Pages 1331-1339

  De Jong, P H ^a   Hazes, J M ^a   Han, H K ^b   Huisman, M ^c   Van Zeben, D ^c   Van Der Lubbe, P A ^d   Gerards, A H ^d   Van Schaeybroeck, B ^e   De Sonnaville, P B ^f,g   Van Krugten, M V ^f,g   Luime, J J ^a   Weel, A E ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Maasstad Hospital Rotterdam   (Netherlands)

^c Department of Rheumatology Sint Francicus Gasthuis Hospital ^*  (Netherlands)

^d Vlietland Hospital   (Netherlands)

^e ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^f Admiraal de Ruyter Hospital   (Netherlands)

^g Admiraal de Ruyter Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE; TRIAMCINOLONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW DEPRESSION; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DYSPNEA; EDEMA; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; HAIR LOSS; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEARING IMPAIRMENT; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MUSCLE WEAKNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE BLIND PROCEDURE; SKIN DISEASE; SLEEP DISORDER; VISUAL IMPAIRMENT;

DMARDS (SYNTHETIC); EARLY RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS; TREATMENT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; INJECTIONS, INTRAMUSCULAR; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; SINGLE-BLIND METHOD; SULFASALAZINE; TREATMENT OUTCOME;

EID: 84902259577     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204788     Document Type: Article

References (36)

1. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
2. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
3. Aletaha D, Neogi T, Silman AJ 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
4. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
5. Arnett FC, Edworthy SM, Bloch DA,, et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
6. O'Dell JR, Haire CE, Erikson N,, et al Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91. (Pubitemid 26138009)
7. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF,, et al Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2005;52:3381-90. (Pubitemid 41612204)
8. Mottonen T, Hannonen P, Leirisalo-Repo M,, et al Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73. (Pubitemid 29219206)
9. Boers M, Verhoeven AC, Markusse HM,, et al Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18. (Pubitemid 27351112)
10. Moreland LW, O'Dell JR, Paulus HE,, et al A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64:2824-35.
11. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? Arthritis Rheum 2005;52:2975-83. (Pubitemid 41447076)
12. Katchamart W, Trudeau J, Phumethum V, et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: A systematic review and meta-analysis. Ann Rheum Dis 2009;68:1105-12.
13. Hoes JN, Jacobs JW, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010;6:693-702.
14. Claessen SJ, Hazes JM, Huisman MA, et al. Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial. BMC Musculoskelet Disord 2009;10:71.
15. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65. (Pubitemid 34136572)
16. van der Heijde DM, van 't Hof M, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81. (Pubitemid 23102498)
17. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40. (Pubitemid 26036375)
18. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
19. Siegert CE, Vleming LJ, Vandenbroucke JP, et al. Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984;3:305-9. (Pubitemid 15072110)
20. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743-5. (Pubitemid 29125603)
21. van Tuyl LH, van der Heijde D, Knol DL, et al. Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. Ann Rheum Dis 2014;73:391-5.
22. van der Heijde D, Simon L, Smolen J,, et al How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 2002;47:215-18. (Pubitemid 34303850)
23. Stucki G, Liang MH, Stucki S, et al. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995;38: 795-8.
24. Nederlandse Vereniging van Reumatologie. NVR Richtlijnen medicijnen: methotrexaat. 2009:1-4. http://www.nvr.nl/uploads/ki/tO/kitOmw9WmZQBHEq61H4YMQ/ NVR-Medicijnen-MTX-richtlijn-2009-update-2011.pdf (accessed 27 Apr 2014).
25. Nederlandse Vereniging van Reumatologie. NVR Richtlijnen medicijnen: sulfasalazine. 2002:1-6. http://www.nvr.nl/uploads/ki/tO/kitOmw9WmZQBHEq61H4YMQ/ NVR-Medicijnen-richtlijn-Sulfasalazine-2002.pdf (accessed 27 Apr 2014).
26. Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-35. (Pubitemid 47585417)
27. van Vollenhoven RF, Geborek P, Forslind K,, et al Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379:1712-20.
28. O'Dell JR, Mikuls TR, Taylor TH,, et al Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369:307-18.
29. Schoels M, Wong J, Scott DL,, et al Economic aspects of treatment options in rheumatoid arthritis: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
30. Chaparro Del Moral R, Rillo OL, Casalla L,, et al Work productivity in rheumatoid arthritis: relationship with clinical and radiological features. Arthritis 2012;2012:137635.
31. Barnabe C, Thanh NX, Ohinmaa A,, et al Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. Ann Rheum Dis 2013;72:1664-8.
32. Pasma A, Van't Spijker A, Hazes JM, et al. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: A systematic review. Semin Arthritis Rheum 2013;43:18-28.
33. de Jong PH, Quax RA, Huisman M,, et al Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3 months: post hoc analyses from the tREACH study. Ann Rheum Dis 2013;72: 1659-63.
34. Klarenbeek NB, van der Kooij SM, Guler-Yuksel M,, et al Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70: 315-19.
35. den Uyl D, Ter Wee M, Boers M, et al A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 2014;73:1072-9.
36. van der Heijde D, van der Helm-van Mil AH, Aletaha D, et al EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 2013;72:479-81.